Log in to your Inderes Free account to see all free content on this page.

Xintela

0.23 SEK

-5.39%

Less than 1K followers

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Xintela

2019202020212022202320242025
Revenue0.00.14.22.3
growth-%5,175.0 %-45.9 %
EBITDA-38.0-30.3-40.1-69.1-57.2-39.5-46.1
EBIT-38.0-33.9-43.6-69.1-57.2-39.5-46.7
Profit before taxes-38.1-50.3-44.1-73.2-58.4-41.5-50.2
Net income-43.5-50.3-58.4-66.2-54.1-39.2-48.6
EPS-0.61-0.40-0.38-0.37-0.13-0.07-0.07
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %
Login required

This content is only available for logged in users

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-100,123.7 %-71,550.0 %-934.8 %-2,019.2 %
EBIT-%-100,123.7 %-71,550.0 %-934.8 %-2,045.7 %
ROE-466.9 %-182.0 %-1,479.5 %-1,145.7 %-1,234.7 %658.7 %921.0 %
ROI-254.7 %-103.6 %-236.0 %-270.1 %-293.9 %-158.0 %-167.3 %
Login required

This content is only available for logged in users